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the disease was developed and the study adopted society’s perspective while the
horizon time considered was patient’s remaining lifespan. Cohorts of COPD pa-
tients treated with Tiotropium or cohorts of patients undergoing pulmonary reha-
bilitation programs were simulated (Monte-Carlo simulations in TreeAge software)
and compared to identical cohorts of patients subjected to usual care. Life expec-
tancies, quality adjusted life-years (QALY), disease-related costs, and incremental
cost-utility ratios were estimated. RESULTS: At the horizon of a patient’s remain-
ing lifetime (14.29 life years in average, considering a population combining mod-
erate to very severe patients), tiotropium would result in 0.12 life years and 0.58
QALY gained (mean estimates), induce an additional cost of 5380 €/patient in the
disease-related costs, with a corresponding incremental cost-utility ratio of 8853
€/QALY. For pulmonary rehabilitation programs, these estimates were 0 life years,
0.31 QALY, 2,969 €, and 12,000 €/QALY, respectively. Results were mostly sensitive
to the utility changes associated with exacerbations. CONCLUSIONS: Tiotropium
treatment and pulmonary rehabilitation programs were estimated as worth inter-
ventions in the studied population, below the usual threshold used for declaring
procedures as cost effective. Nevertheless, the modest gains in health issued from
the study emphasize the need of research for developing more effective COPD-
related therapies.
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OBJECTIVES: To assess costs, utilities and cost-utility of fixed combination salme-
terol/fluticasone (SAL/FP maintenance treatment) versus non-fixed combination
budesonide  formoterol in one pack (BUDFORM maintenance treatment) in the
management of patients with bronchial asthma by means of an OPTIMA model.
METHODS: In this analysis we used the following data: drug prices (from List of
Maximum Permissible Manufacturer Prices for Vital and Essential Drugs) and drug
dosage proportion (from MRC Pharmexpert, 4Q 2010); number of inhalations per
day (from instructions); QOL and number of health care resources for controlled
and uncontrolled asthma (from published sources); resource unit costs (from 2010
health care insurance program). Work-off day costs included tax deficiency, GDP
underproduction and sick pay. Frequency of controlled asthma was obtained from
ARROW study (Ogorodova et al., 2009) for SAL/FP (73%) and from FACET trial
(O’Byrne et al. 2008) for BUDFORM (62%). Conceptual formula of analysis was: cost
of drugs% controlled * cost of controlled% uncontrolled * cost of uncontrolled.
One-way sensitivity analysis was conducted to assess the robustness of the results.
RESULTS: Average monthly costs of drugs were 1,677 RUR/€42 and 2,023 RUR/€51
for SAL/FP and BUDFORM respectively. Medical costs and QOL measures were 378
RUR/€9 and 0.75 for controlled asthma; 88,295/€2,207 RUR and 0.49 for uncontrolled
asthma. Yearly total costs per patient were higher for BUDFORM than for SAL/FP
(58,057/€1,451 RUR vs. 44,244 RUR/€1,106). Compared to BUDFORM, SAL/FP was
associated to an expected increase of QALYs per patient (0.68 QALYs vs. 0.65
QALYs). The cost-utility analysis showed that SAL/FP was dominant (less costly
and more effective in terms of QALYs gained). Results were sensitive to all the
parameters varied in the sensitivity analysis, especially health care costs.
CONCLUSIONS: Treatment of patients with bronchial asthma with SAL/FP is a
dominant strategy in comparison with non-fixed combination BUDFORM in one
pack.
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OBJECTIVES: Smoking is the leading cause of preventable death in El Salvador
(50%) and results in many serious comorbidities, including lung cancer, coronary
heart disease, stroke and chronic respiratory disease. The aim of this study was to
evaluate the cost-utility of varenicline compared to other existing strategies for
smoking cessation within a 5-year time horizon in El Salvador using the healthcare
payer’s perspective. METHODS: The Benefits of Smoking Cessation on Outcomes
(BENESCO) simulation model was used for an adult cohort (n4,537,803). Diseases
included were: stroke, lung cancer, coronary heart disease and chronic obstructive
pulmonary disease. Smoking cessation therapies compared were: varenicline (0.5 –
2 mg/day), bupropion (300 mg/day), nicotine replacement treatment (NRT) (5-10
mg/day) and unaided cessation. Effectiveness measure was: quality-adjusted life
year gained (QALY’s), which was obtained from published literature. Resource use
and costs data were obtained from El Salvador’s Ministry of Health and Social
Security official databases (2010). The model used a 3% discount rate for costs
(expressed in 2010 US dollars) and QALYs. Probabilistic sensitivity analyses (PSA)
were conducted and acceptability curves were constructed. RESULTS: Varenicline
reduced smoking related morbidity, mortality and healthcare costs. After 5 years,
Varenicline gained 306,158 QALYs, which represents 73, 94 and 178 more QALYs
than bupropion, NRT and unaided cessation, respectively. Overall costs showed
varenicline as the least expensive option against bupropion (US$328,558), NRT
(US$412,730) and unaided cessation (US$777,124). Cost-effectiveness analyses
showed that varenicline was the dominant strategy. Acceptability curves showed
that varenicline would be cost-effective within 3 GDP per capita threshold. PSA
results support the robustness of the findings. CONCLUSIONS: Smoking cessation
therapy with varenicline is cost-saving in El Salvador. These results could help to
reduce the tobacco related disease burden and align cost-containment policies.
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OBJECTIVES: To estimate annual medical and productivity costs attributable to
obesity in adult patients with asthma in the US. METHODS: This study used the
2003-2008 Medical Expenditure Panel Survey. Asthma patients(18-64 years) were
identified using ICD-9-CM code 493, clinical classification code-128, or physician
diagnosis. Patients were classified as normal(BMI:18.5-25 kg/m2), overweight-
(BMI:25-30 kg/m2) or obese(BMI:30 kg/m2). Medical costs were estimated using
a generalized linear model(GLM) with a log link function and gamma distribution.
Costs associated with productivity loss were calculated based on missed working
days due to illness and average hourly wage using a two part model. In the first
part, logistic regression was used to estimate the probability of having missed
working days due to illness. In the second part, among patients with missed work-
ing days, GLM was used with the estimated probability from first part of model to
estimate the cost associated with productivity loss. The costs attributable to obe-
sity were estimated by differences between the observed and estimated cost in
obese patients, using a distribution of covariates obtained from normal patients.
All costs were converted to 2010 US dollars using price indices. RESULTS: A total of
8775 adults were identified with asthma. The average treatment cost and lost pro-
ductivity costs of normal patients were $3154(95%CI:$2689-$3620) and $327(95%CI:
$279-$375), and those of obese patients were $5720(95%CI:$5314-$6129) and
$699(95%CI:$608-$790), respectively. Obese patients had 38% higher medical cost
and 53% higher lost productivity costs after adjusting for other study variable.Ad-
ditional medical costs attributable to obesity were calculated at $1087 (95%CI:$687-
$1487) and lost productivity costs attributable to obesity were $279(95%CI:$191-$368).
CONCLUSIONS: The economic burden of asthma among US adults is substantial
which is only further amplified by the presence of obesity. This study highlights the
importance of obesity control to reduce the cost of treating asthma patients and
enhance productivity.
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OBJECTIVES: The objective is to describe the healthcare resource utilization and
cost patterns associated with severe uncontrolled allergic asthma, based on data
from Dutch patients collected in the EXPERIENCE study. METHODS: EXPERIENCE
was a prospective, open-label, observational, multicenter, multicountry study in
patients with severe persistent allergic asthma treated with omalizumab. The
Global Evaluation of Treatment Effectiveness (GETE) was used to evaluate patient
response. Healthcare resource use and number of exacerbations were captured for
one year prior to the start of the study for all patients and continued for 104 weeks
until end of the study. Hospitalizations, specialist visits and medications were
included in this analysis for year before study and first year of study. Unit cost
prices taken from 2010. RESULTS: A total of 154 subjects were included in ITT
population. There were 2.5 clinically significant (CS) exacerbations/patient year
prior compared to 0.90 CS exacerbations/patient for year of study on omalizumab.
The total number of CS severe (CSS) exacerbation was 0.95 CCS exacerbations/
patient for year prior and 0.26 CSS exacerbations/patient for year of study. The
results indicate that patients in this study have an average cost of €4257/patient in
the year prior to the study and €2583/patient cost during the study year, excluding
omalizumab costs. The biggest cost drivers are hospitalization, work days lost and
other asthma medications. The total omalizumab costs were €12,652/patient plus
€1,171/patient for administration cost. CONCLUSIONS: This study reflects real life
clinical practice and associated costs for omalizumab treatment of severe allergic
asthma patients. It indicates a reduction in CS and CSS exacerbation rates of 64%
and 73%, respectively associated with a 40% reduction in treatment costs when
using omalizumab. Keeping in mind the study limitations associated with the
observational setting, it provides estimated costs for patients with severe uncon-
trolled allergic asthma based on ‘real-world’ Dutch practice patterns.
Respiratory-Related Disorders – Patient-Reported Outcomes & Preference-Based
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